scholarly journals P457 IBD couples and their offspring: a European survey

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S407-S408
Author(s):  
A Oliveira ◽  
M P Costa-Santos ◽  
C Frias Gomes ◽  
J Sabino ◽  
A Sampaio ◽  
...  

Abstract Background Small studies have shown that the frequency of inflammatory bowel disease (IBD) is significantly increased after marriage to an individual with the disease relative to what would be expected by chance alone. Furthermore, the offspring of these couples have a significantly increased risk of developing the disease. The aim of this study was to identify couples where both spouses have IBD and their offspring in a larger cohort and to characterise their phenotype. Methods This was a cross-sectional study including couples where both members were affected with IBD and their offspring. An electronic survey in seven languages was distributed by the European Crohn’s and Colitis Organization (ECCO), European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) and national patient′s associations from June 2018 to December 2019. Results We identified 51 couples where both members had IBD. There was consanguinity in one couple. There was a representation of couples living in nine different countries. Thirty (59%) couples were concordant for IBD, 14 for Crohn’s disease (CD) and 16 for ulcerative colitis (UC). Within 49 couples, 21 (43%) were diagnosed prior to cohabitation, in 7 (14%) one spouse was diagnosed before and the other after a mean of 7.2 ± 8.9 years after cohabitation, and in 21 (43%) the onset of disease was after cohabitation for both (the first member developed IBD after a mean of 8.3 ± 8.4 years of cohabitation and the second one 4.1 ± 4.5 years after the first). The prevalence of IBD in the 58 children born from these couples was 9%. The cumulative probability of developing disease in the progeny was 3% at 10 years, 11% at 15 years and 15% at 20 years of age. Conclusion This survey identified 51 couples with IBD across Europe; 59% were concordant for IBD type and in 57% the diagnosis of at least one spouse was made after cohabitation. In a wider population, the risk for the progeny was at most 15% at the age of 20, lower than previously reported.

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 55
Author(s):  
Mohammad Shehab ◽  
Yasmin Zurba ◽  
Ali Al Abdulsalam ◽  
Ahmad Alfadhli ◽  
Sara Elouali

Background: COVID-19 vaccinations have been shown to be effective in reducing risk of severe infection, hospitalization, and death. They have also been shown to be safe and effective in patients with inflammatory bowel disease (IBD) who are receiving biologic therapies. In this study, we aimed to evaluate the prevalence of vaccination among patients receiving biologic therapies for IBD. Methods: A single-center prospective cross-sectional study conducted at a tertiary care inflammatory bowel disease center in Kuwait. Data from patients with inflammatory bowel disease (IBD) who attended the gastroenterology infusion clinic from 1 June 2021 until 31 October 2021 were retrieved. Patients who received infliximab or vedolizumab at least six weeks before recruitment were included. The primary outcome was prevalence of COVID-19 vaccination. The secondary outcome was to assess whether prevalence of COVID-19 vaccination differed based on sex, age, type of biologic therapy and nationality. Results: The total number of inflammatory bowel disease (IBD) patients enrolled in the study was 280 (56.0% male and 44.0% female). Of the total, 112 (40.0%) patients were diagnosed with ulcerative colitis and 168 (60.0%) with Crohn’s disease. The number of ulcerative colitis patients who were vaccinated was 49 (43.8%) and the number of Crohn’s disease patients who were vaccinated was 68 (40.5%). The median age was 33.2 years and BMI was 24.8 kg/m2. With respect to the total number of patients, 117 (41.8%) were vaccinated with either BNT162b2 or ChAdOx1 nCoV-19 and 163 (58.2%) were not vaccinated. Female patients were more likely to receive the vaccine compared to male patients (83.0% vs. 63.8%, p < 0.001). In addition, patients above the age 50 were more likely to receive the vaccine than patients below the age of 50 (95.6% vs. 31.2% p < 0.001). Expatriates were more likely to receive the vaccine than citizens (84.8% vs. 25.0%, p < 0.001). There was no statistical difference between patients on infliximab and vedolizumab with regard to prevalence of vaccination (40.0% vs 48.0%, p = 0.34). Conclusion: The overall prevalence of COVID-19 vaccination among patients with inflammatory bowel disease (IBD) on biologic therapies was lower than that of the general population and world health organization (WHO) recom-mendation. Female patients, patients above the age of 50, and expatriates were more likely to receive the vaccine. Physicians should reinforce the safety and efficacy of COVID-19 vaccines among patients, especially IBD patients on biologic therapies, who express hesitancy towards them.


PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0252458
Author(s):  
Doreen Busingye ◽  
Allan Pollack ◽  
Kendal Chidwick

The burden of inflammatory bowel disease (IBD) in Australia is increasing but national data about the current prevalence are limited. We aimed to estimate the prevalence of IBD (including Crohn’s disease, ulcerative colitis and unspecified IBD) as well as Crohn’s disease and ulcerative colitis separately in a general practice population in Australia. We also assessed risk factors associated with Crohn’s disease and ulcerative colitis. We conducted a cross-sectional study using data from MedicineInsight, a national database of general practice electronic health records, from 1 July 2017 to 30 June 2019. The prevalence of IBD was calculated and stratified by sociodemographic characteristics. Logistic regression analysis was conducted to assess risk factors associated with Crohn’s disease and ulcerative colitis. The study comprised 2,428,461 regular patients from 481 practices. The estimated crude prevalence of IBD was 653 per 100,000 patients; Crohn’s disease was 306 per 100,000 and ulcerative colitis was 334 per 100,000. Males were independently associated with a lower risk of Crohn’s disease (OR: 0.86; 95% CI: 0.81, 0.90) but a greater risk of ulcerative colitis (OR: 1.12; 95% CI: 1.06, 1.17) than females. Compared to non-smokers, patients who were current smokers were associated with a greater risk of Crohn’s disease (OR: 1.13; 95% CI: 1.04, 1.23) but a lower risk of ulcerative colitis (OR: 0.52; 95% CI: 0.47, 0.57). Other factors positively associated with both Crohn’s disease and ulcerative colitis were age (≥ 25 years), non-Indigenous status and socioeconomic advantage. Our findings provide a current estimate of the prevalence of IBD, Crohn’s disease and ulcerative colitis in a large national general practice population in Australia and an assessment of the factors associated with Crohn’s disease and ulcerative colitis. These data can assist in estimating the health burden and costs, and planning for health services.


2021 ◽  
Vol 1 (6) ◽  
pp. 29-39
Author(s):  
Yu. P. Uspenskiy ◽  
S. V. Ivanov ◽  
Yu. A. Fominikh ◽  
M. M. Galagudza

Background. Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) are serious problem in modern gastroenterology, as these diseases affect the working population, have a progressive chronic course, a high risk of disabling complications and require significant costs for the drug management.Aim. We wanted to assess the inflammatory bowel diseases structure and features of the use of basic drugs in outpatient and inpatient treatment in St. Petersburg, Russia.Materials and methods. A cross-sectional study was performed. Data about drug therapy, disease features and demographic from 42 outpatient institutions and from 6 city hospitals for the period 2018–2020 in St. Petersburg was collected. The analysis included data from 617 patients with ulcerative colitis and 455 patients with Crohn’s disease.Results. The median age of patients with ulcerative colitis was 44 years, which was statistically significant more than with Crohn’s disease (39 years). In ulcerative colitis, the left-sided localization of colon lesions (56%) prevailed over total colitis (23%) and proctitis (21%) In Crohn’s disease, the prevalence of ilecocolitis (36%) was approximately equal to the prevalence of colitis (35%), the frequency of terminal ileitis was significantly less (26%), other variants of gastrointestinal lesions were found in 3% cases. In Crohn’s disease compared to ulcerative colitis, the proportion of patients with mild disease was similar (36.6% and 38.2% respectively), but in in Crohn’s disease the frequency of severe disease there was more than three times compared to ulcerative colitis. There has been a significantly higher incidence of surgery in the past for Crohn’s disease compared to ulcerative colitis (14.8% and 2.6%, respectively). The vast majority of patients (more than 80%) received therapy with oral 5-aminosalycilic acid drugs. Topical formulas of 5-aminosalycilic acid drugs in ulcerative colitis were prescribed in about 50% of cases (it was significantly less than commonly used in Crohn’s disease). Corticosteroids were used in the treatment of 16.6% of ulcerative colitis patients and in 24.4% Crohn’s disease patients. In both diseases in the conditions of inpatient treatment, this group of drugs was used several times more often than in outpatient observation. Immunosuppressants (tyopurines, methotrexate) were administered in 6.9% ulcerative colitis patients with and in 17.0% Crohn’s disease patients.Conclusion. Clinical features of inflammatory bowel diseases in St. Petersburg and the features of basic therapy in comparison with the nationwide indicators in Russia demonstrate similar trends. The key problem points of therapy of inflammatory bowel diseases remains the widespread use of drugs of the group of 5-aminosalycilic acid in Crohn’s disease, insufficient use of rectal forms of 5-aminosalycilic acid in ulcerative colitis, a relatively small frequency of use of immunosupressors to maintain remission in Crohn’s disease. The solution to the problem of optimizing the therapy of patients with inflammatory bowel diseases within the framework of routine practice includes educational activities, as well as the creation of a regional register of patients with inflammatory bowel diseases in St. Petersburg.


Nutrients ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1936 ◽  
Author(s):  
Dominika Skolmowska ◽  
Dominika Głąbska ◽  
Dominika Guzek ◽  
Gustaw Lech

Currently there are contradictory observations regarding the associations between the isoflavone intake and inflammatory bowel disease in terms of its prevention and treatment, and this may be attributed to the diversity of applied doses and influence of various isoflavones. The aim of the presented cross-sectional study is to analyze the association between intake of various isoflavones (daidzein, genistein, glicytein and total isoflavones) and ulcerative colitis symptoms (fecal blood, mucus and pus) in Polish Caucasian individuals in confirmed remission. Assessment of diet was based on self-reported data obtained from patients’ three-day dietary records and their individual assessments of symptoms. A total of 56 Caucasian patients with ulcerative colitis in confirmed remission were recruited for the study (37 females and 19 males, aged 18–80). For individuals with no fecal mucus observed, higher daidzein (p = 0.035, 122 vs. 19 µg) and total isoflavone intakes (p = 0.034, 302.2 vs. 123.7 µg) were observed in comparison with individuals not declaring this symptom, while for daidzein it was confirmed for the component density of their diets. The opposite association was stated for fecal pus, as for individuals with a lack of this symptom, lower daidzein intake was stated in comparison with individuals declaring this symptom (p = 0.049, 103.3 vs. 206.7 µg), but it was not confirmed for the component density of the diets. It was stated that the high intake of isoflavones by Caucasian individuals, as in a western diet, may influence the symptoms of ulcerative colitis, with the strongest influence by daidzein. Taking this into account, isoflavones may be included into the diets of ulcerative colitis patients in remission if well-tolerated, but there is a need for further study.


2021 ◽  
Author(s):  
Harith AL-Amri ◽  
Salim Al-Huseini ◽  
Moon Fai Chan ◽  
Alkhatib Al Saadi ◽  
Nasser Al-Sibani ◽  
...  

Objectives: Many studies suggest that depression is prevalent among patients suffering from inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Notably, both depression and IBD have a significant disease burden. However, these studies have mostly been conducted among European and American populations; there is a paucity of these studies from Arabic countries. This study aimed to examine the prevalence and predictors of depressive symptoms among adult IBD patients attending a tertiary care hospital in Muscat, Oman. Methods: This was a cross-sectional study, conducted among a random sample of patient's aged18 years and older who attended the gastroenterology clinic at Sultan Qaboos University Hospital, Muscat, Oman between June 2018, and January 2019. Participants were asked to complete the Patient Health Questionnaire-9 (PHQ-9) to assess depression, as well as a sociodemographic survey. Logistic regression analysis was used to identify the independent predictors of depressive symptoms among the study sample. Adjusted odds ratios (OR) were also reported. Results: This study included 201participants, within average age of 36years. Of this study, 51% were female. The mean duration of the patients’IBD diagnosis was 1.9 years (standard deviation=0.3), the majority of the participants (87%) had ulcerative colitis (n=174), 80% of the participants had received steroids (n=161), and 6% of the sample had a history of a surgical stoma. The medical comorbidities among the participants were cerebrovascular accidents (25%), hypertension (25%) and diabetes mellitus (24%). The prevalence of depressive symptoms was 23%. The logistic regression analysis resulted in four independent predictors of depression: being female (odds ratio [OR] =2.09, P=0.047), a history of surgical stoma (OR=5.737, P<.001), a comorbid diagnosis of hypertension (OR=2.846, P=0.007), and a history of a cerebrovascular accident (OR=2.651, P=0.011). Conclusion: The present study found that depressive symptoms are prevalent among Omani patients with IBD. Certain clinical factors appeared to increase the risk of depression among this population. The findings of this study fill a gap in the existing literature and call for further work aiming at screening and managing depression among IBD patients.


Sign in / Sign up

Export Citation Format

Share Document